Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil: A prospective cohort study

Chemotherapy

Volumn 49, Issue 1-2, 2003, Pages 85-89

  Moehler, Markus ^a,b   Gutzler, Frank ^b   Steinmann, Silke ^a   Boehme, Michael ^a   Raeth, Ulrich ^b   Stremmel, Wolfgang ^b   Galle, Peter R ^a,b   Rudi, Jochen ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 Fluorouracil; Chemotherapy; Continuous infusion; Folinic acid; Metastatic colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ERYTHRODERMA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR REGRESSION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 0344511616     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069778     Document Type: Article

References (31)

1. Schmoll HJ, Buchele T, Grothey A, Dempke W: Where do we stand with 5-fluorouracil? Semin Oncol 1999;26:589-605.
2. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3,825 patients. Ann Oncol 2002;13: 308-317.
3. Grothey A, Schmoll HJ: New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001;13:275-286.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
6. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7: 1419-1426.
7. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994;5:233-237.
8. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
9. Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluoroura-cil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
10. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352: 1413-1418.
11. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
12. André TBM, Louvet C: Multicenter phase II study of bimonthly highdose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistance to the same leucovorin and fluorouracil regime. J Clin Oncol 1999;17:3560-3568.
13. Maindrault-Goebel FLC, André T: GERCOR. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999;35:1338-1342.
14. Kohne CH, Schoffski P, Wilke H: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
15. Aranda E, Dorta J: A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1998;9:727-731.
16. Schmoll HJ, Kohne CH, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz MP, Kleeberg U, Ridwelski K, Souchon R, El-Safari M, Weiss U, Couvreur ML, Baron B, Wils JA: Weekly 24 h infusion of high-dose (HD) 5-fluorouracil (5FU24h) with or without folinic acid (FA) vs. bolus 5-FU/Fa (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO. Proc Asco 2000;19: 241.
17. Shah A, MacDonald W, Goldie J, Gudauskas G, Brisebois B: 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 1985;69:739-742.
18. Bruce D, Minsky M: Role of adjuvant therapy in adenocarcinoma of the rectum. Semin Surg Oncol 1999;17:189-198.
19. Pitot HC, Goldberg RM: Future directions in adjuvant therapy for stage III colon carcinoma Oncology (Huntingt) 2001;15(3 suppl 5):31-36.
20. Poon MA, Oc MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9:1967-1972.
21. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Delouche C, Brochon D, Fraioli JP, Jasmin C, Maral R, Mathe G: Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study. Sem Hop 1982;58:1873-1875.
22. Ardalan B, Luis R, Jaime M, Franceschi D: Biomodulation of fluorouracil in colorectal cancer. Cancer Invest 1998;16:237-251.
23. Shackney SE: Cell kinetics and cancer chemotherapy. New York, MacMillan, 1985.
24. Laufman LR, Bukowski RM, Collier MA, Sullivan BA, McKinnis RA, Clendennin NJ, Guaspari A, Brenckman WD Jr: A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993;11:1888-1893.
25. MacMillan WE, Wolberg WH, Welling PG: Pharmacokinetics of fluorouracil in humans. Cancer Res 1978;38:3479-3482.
26. Grem JL: Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. Oncology (Huntingt) 2001;15(1 suppl 2): 13-19.
27. Twelves C, Xeloda Colorectal Cancer Group: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 2002;38(suppl 2):15-20.
28. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-630.
29. Blijham GH: The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer. J Infus Chemother 1996;6:114-117.
30. Tournigand CLC, Quinaux EM: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001;20:494A.
31. Richard M, Goldberg RFM, Sargent DJ: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/Leucovorin (LV) or Oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup Study. Proc Am Soc Clin Oncol 2002;21:511a.